Raebel Marsha A, Lyons Ella E, Chester Elizabeth A, Bodily Michael A, Kelleher Julia A, Long Charron L, Miller Chad, Magid David J
Clinical Research Unit, Kaiser Permanente of Colorado, Denver, CO 80237-8066, USA.
Arch Intern Med. 2005 Nov 14;165(20):2395-401. doi: 10.1001/archinte.165.20.2395.
The importance of laboratory monitoring for drugs is reflected in product labeling and published guidelines, but monitoring recommendations are followed inconsistently. Opportunity exists to improve monitoring, with the potential to decrease therapy complications.
The objective of this randomized trial was to determine whether computerized alerts were effective at increasing the percentage of ambulatory patients with laboratory monitoring at initiation of drug therapy. Physicians and pharmacists teamed up to develop organization-specific guidelines for monitoring selected drugs. In collaboration with physicians, pharmacists were alerted to missing laboratory test results, ordered missing tests, reminded patients to obtain tests, assessed test completion, reviewed test results, and managed abnormal results. Eligible individuals included patients with therapy initiated for any of 15 drugs among 400,000 health plan members.
In the intervention group, 79.1% (n = 4076; 95% confidence interval [CI], 78.0%-80.2%) of dispensings were monitored compared with 70.2% (n = 3522; 95% CI, 68.9%-71.5%) in the usual-care group (P < .001). For example, 78.6% of amiodarone (95% CI, 73.1%-83.5%) dispensing was monitored in the intervention group vs 51.4% (95% CI, 44.4%-58.4%) in the group receiving usual care (P < .001).
This study demonstrates the effectiveness of a computerized tool plus collaboration among health care professionals at increasing the percentage of patients receiving laboratory monitoring at initiation of therapy. Coupling data available from information systems with the knowledge and skills of physicians and pharmacists can result in improved patient monitoring.
药物实验室监测的重要性在产品标签和已发布的指南中有所体现,但监测建议的遵循情况并不一致。存在改善监测的机会,这有可能减少治疗并发症。
这项随机试验的目的是确定计算机化警报在提高药物治疗开始时进行实验室监测的门诊患者比例方面是否有效。医生和药剂师合作制定了针对特定组织的选定药物监测指南。药剂师与医生合作,收到实验室检查结果缺失的警报,开出缺失的检查单,提醒患者进行检查,评估检查完成情况,审查检查结果,并处理异常结果。符合条件的个体包括40万健康计划成员中因15种药物中的任何一种开始治疗的患者。
干预组中有79.1%(n = 4076;95%置信区间[CI],78.0%-80.2%)的配药接受了监测,而常规护理组为70.2%(n = 3522;95%CI,68.9%-71.5%)(P <.001)。例如,干预组中78.6%(95%CI,73.1%-83.5%)的胺碘酮配药接受了监测,而接受常规护理的组为51.4%(95%CI,44.4%-58.4%)(P <.001)。
本研究证明了计算机化工具加上医疗保健专业人员之间的合作在提高治疗开始时接受实验室监测的患者比例方面的有效性。将信息系统中的可用数据与医生和药剂师的知识和技能相结合可以改善患者监测。